VHCP Management II, LLC Buys Tricida Inc, DBV Technologies SA, Kiniksa Pharmaceuticals, Sells AveXis Inc, AnaptysBio Inc, DBV Technologies SA

• New Purchases: TCDA, DBVT, KNSA, KDMN, MRNS, APLS, CCXI,
• Added Positions: OBSV, BCRX, BHVN,
• Reduced Positions: ASND, SPRO,
• Sold Out: AVXS, ANAB, DBVTF, MNLO, SVRA,

For the details of VHCP Management II, LLC's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=VHCP+Management+II%2C+LLC

1. Endocyte Inc (ECYT) - 4,300,000 shares, 17.76% of the total portfolio.
2. Biohaven Pharmaceutical Holding Co Ltd (BHVN) - 1,415,391 shares, 16.74% of the total portfolio. Shares added by 1.80%
3. ObsEva SA (OBSV) - 2,252,460 shares, 10.21% of the total portfolio. Shares added by 5.07%
4. Ascendis Pharma A/S (ASND) - 504,210 shares, 10.04% of the total portfolio. Shares reduced by 13.99%
5. argenx SE (ARGX) - 346,792 shares, 8.68% of the total portfolio.

VHCP Management II, LLC initiated holding in Tricida Inc. The purchase prices were between $26 and $29.9, with an estimated average price of $27.95. The stock is now traded at around $23.50. The impact to a portfolio due to this purchase was 8.62%. The holding were 962,696 shares as of 2018-06-30.

VHCP Management II, LLC initiated holding in DBV Technologies SA. The purchase prices were between $18.6 and $24.94, with an estimated average price of $22.54. The stock is now traded at around $19.00. The impact to a portfolio due to this purchase was 3.6%. The holding were 463,149 shares as of 2018-06-30.

VHCP Management II, LLC initiated holding in Kiniksa Pharmaceuticals Ltd. The purchase prices were between $16.73 and $20.35, with an estimated average price of $18.13. The stock is now traded at around $14.68. The impact to a portfolio due to this purchase was 3.32%. The holding were 639,230 shares as of 2018-06-30.

VHCP Management II, LLC initiated holding in Kadmon Holdings Inc. The purchase prices were between $3.35 and $4.39, with an estimated average price of $3.91. The stock is now traded at around $3.47. The impact to a portfolio due to this purchase was 1.69%. The holding were 1,411,428 shares as of 2018-06-30.

VHCP Management II, LLC initiated holding in Marinus Pharmaceuticals Inc. The purchase prices were between $3.8 and $7.7, with an estimated average price of $5.53. The stock is now traded at around $5.98. The impact to a portfolio due to this purchase was 0.73%. The holding were 345,240 shares as of 2018-06-30.

VHCP Management II, LLC initiated holding in Apellis Pharmaceuticals Inc. The purchase prices were between $19.63 and $30, with an estimated average price of $23.02. The stock is now traded at around $18.46. The impact to a portfolio due to this purchase was 0.2%. The holding were 29,710 shares as of 2018-06-30.

VHCP Management II, LLC sold out a holding in AveXis Inc. The sale prices were between $115.91 and $217.83, with an estimated average price of $198.8.

VHCP Management II, LLC sold out a holding in AnaptysBio Inc. The sale prices were between $70.01 and $96.33, with an estimated average price of $83.98.

VHCP Management II, LLC sold out a holding in DBV Technologies SA. The sale prices were between $44.24 and $48.46, with an estimated average price of $45.69.

VHCP Management II, LLC sold out a holding in Menlo Therapeutics Inc. The sale prices were between $7.79 and $36.99, with an estimated average price of $10.83.

VHCP Management II, LLC sold out a holding in Savara Inc. The sale prices were between $8.55 and $13.76, with an estimated average price of $10.03.